The power of PRALUENT

LDL-C reductions with 75 mg and 150 mg1

View PRALUENT efficacy


Who is PRALUENT for?

Patients you often see in clinical practice

View PRALUENT patient types


Dosing flexibility

2 doses with 2 levels of efficacy1

Learn more about PRALUENT dosing


Savings and long-term support

Comprehensive assistance with cost, coverage, and more

Get started today with MyPRALUENT®


Now available: PRALUENT 300 mg Q4W (monthly), an alternative starting dose, for patients who prefer the flexibility of monthly dosing*

Dosing Information

  • The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously, since the majority of patients achieve sufficient LDL-C reduction with this dosage. An alternative starting dosage for patients who prefer less frequent dosing is 300 mg once every 4 weeks (monthly)
  • Measure LDL-C levels within 4 to 8 weeks of initiating PRALUENT 75 mg Q2W or just prior to the next scheduled dose for patients receiving PRALUENT 300 mg Q4W. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks


  • The once-monthly 300-mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. Three patients (0.7%) treated with PRALUENT 300 mg Q4W discontinued treatment due to local injection site reactions versus no patients (0%) in the other 2 treatment groups
*The 300-mg monthly dose of PRALUENT is administered as 2 consecutive, subcutaneous 150-mg injections at different injection sites every 4 weeks.1

*Formulary data are provided by Managed Markets Insights & Technology, LLC (MMIT) and are current as of April 1, 2016. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage.2


  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2015.